Abstract
The nuclear factor kappa B (NFκB) signalling pathway regulates the expression of hundreds of genes that are involved in different cellular processes such as cell proliferation, survival, stress responses, cellular immunity and inflammation. Its aberrant regulation is involved in several pathologies, but its relevance in cellular transformation and cancer development has been extensively studied. Mutations in the core components of NFκB as well as in the cellular machinery that regulates its activation have been found in many types of tumours. On the other hand, its role in promoting cell survival is an important obstacle in many cancer therapies. The development of chemical inhibitors that block NFκB activation acting either directly on IKKs or on the proteosome machinery has shown antitumour and proapoptotic activity both in preclinical and clinical studies.
Similar content being viewed by others
References
Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8:49–62
Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280–288
Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195–2224
Perkins ND (2003) Oncogenes, tumor suppressors and p52 NF-kappaB. Oncogene 22:7553–7556
Kalaitzidis D, Ok J, Sulak L 2nd et al (2004) Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene 23:7580–7587
Fukuhara N, Tagawa H, Kameoka Y et al (2006) Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma. Cancer Sci 97:499–504
Barth TF, Bentz M, Leithäuser F et al (2001) Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer 31:316–325
Neri A, Fracchiolla NS, Migliazza A et al (1996) The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Leuk Lymphoma 23:43–48
Hinz M, Löser P, Mathas S et al (2001) Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 97:2798–2807
Bours V, Franzoso G, Azarenko V et al (1993). The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72: 729–739
Van Waes C (2007). Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13:1076–1082
Wang CY, Mayo MW, Korneluk RG et al (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683
Guttridge DC, Albanese C, Reuther JY et al (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799
Chen C, Edelstein LC, Gélinas C (2000) The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20:2687–2695
Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33–47
Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108–2121
Davis NB, Taber DA, Ansari RH et al (2004). Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22:115–119
Kondagunta GV, Drucker B, Schwartz L et al (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22:3720–3725
Markovic SN, Geyer SM, Dawkins F et al (2005) A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103:2584–2589
Mackay H, Hedley D, Major P et al (2005) A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11:5526–5533
Yang CH, Gonzalez-Angulo AM, Reuben JM et al (2006) Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17:813–817
Ramirez PT, Landen CN Jr, Coleman RL et al (2008). Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum-and taxane-resistant ovarian cancer. Gynecol Oncol 108:68–71
Davies AM, Ho C, Metzger AS et al (2007) Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol 2:1112–1116
Davies AM, Ruel C, Lara PN et al (2008) The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol 3:68–74
Yang J, Amiri KI, Burke JR et al (2006) BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12:950–960
Lam LT, Davis RE, Pierce J et al (2005) Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11:28–40
Cilloni D, Messa F, Arruga F et al (2006) The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 20:61–67
Yemelyanov A, Gasparian A, Lindholm P et al (2006) Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25:387–389
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by an unrestricted educational grant from Pfizer.
Rights and permissions
About this article
Cite this article
Sempere, M.C., Fanjul, V.R., Pérez, I.S. et al. The role of the NFκB signalling pathway in cancer. Clin Transl Oncol 10, 143–147 (2008). https://doi.org/10.1007/s12094-008-0171-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0171-3